Herpes zoster (HZ) is an acute segmental eruption of herpetiform-grouped vesicles due to endogenous reactivation of varicella-zoster virus (VZV) infection of nerval segments. Treatment of choice is systemic acyclovir and other antiviral agents are available. For elderly people, VZV vaccine is an option in secondary prevention.
- DNA pol
Varicella-zoster virus (VZV)
- Chen N, Yang M, He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2010;(12):CD005582.Google Scholar
- Wassilew S, Collaborative Brivudin PHN Study Group. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol. 2005;19(1):47–55.CrossRefGoogle Scholar
- Cousins MJ, Pickthorn K, Huang S, Critchley L, Bell G. The safety and efficacy of KAI-1678 – an inhibitor of epsilon protein kinase C (εPKC) – versus lidocaine and placebo for the treatment of postherpetic neuralgia: A crossover study design. Pain Med. 2013. doi: 10.1111/pme.12058.CrossRefPubMedGoogle Scholar
- Pentikis HS, Matson M, Atiee G, Boehlecke B, Hutchins JT, Patti JM, et al. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011;55(6):2847–54.CrossRefGoogle Scholar
- Zerngast WW, Paauw DS, O’Connor KM. Varicella zoster with extended prodrome: a case series. Am J Med. 2013;126(4):359–61.Google Scholar